Phase I Trial of Humanized 1D10 Monoclonal Antibody (Hu1D10) In Patients With Relapsed Non-Hodgkin's Lymphoma (NHL)

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed non-Hodgkin's lymphoma in relapse or refractory to prior
treatment

- At least 50% of malignant cells on biopsy specimen reactive with the 1D10 antibody OR
at least 50% of B cells within tumor reactive with 1D10 if extensive T cell
infiltrations present

- Measurable or evaluable disease

- Circulating tumor cells fewer than 5,000/mm3 (in dose escalation phase only)

- Not eligible for curative conventional therapy

PATIENT CHARACTERISTICS:

- Age: 18 and over

- Performance status: ECOG 0-2

- Life expectancy: At least 3 months

- Platelet count at least 75,000/mm3

- Bilirubin less than 2.5 mg/dL

- SGOT less than 3 times upper limit of normal

- Creatinine less than 2.0 mg/dL

- No New York Heart Association class III or IV heart disease

- No clinically significant pulmonary disease

- No active serious infection

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception HIV negative

PRIOR CONCURRENT THERAPY:

- At least 4 weeks since prior interferon

- Concurrent transfusions allowed

- At least 4 weeks since prior cytotoxic chemotherapy

- No concurrent antineoplastic agents

- At least 4 weeks since prior corticosteroids

- No concurrent glucocorticoids

- At least 4 weeks since prior radiotherapy